Copy Link Print Information

Cabozantinib S-malate

(Synonyms: XL184 S-malate; BMS-907351 S-malate)
57 Cited Publications
Customer Review

Based on 57 publication(s) in Google Scholar

Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

For research use only. We do not sell to patients.

  • Purity: 99.90%
  • CAS No.: 1140909-48-3
  • Formula: C32H30FN3O10
  • Molecular Weight:635.59
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Cabozantinib S-malate Chemical Structure
    Cabozantinib S-malate Chemical Structure
  • Experimental Validation Results for Cabozantinib S-malate
  • Experimental Validation Results for Cabozantinib S-malate
  • Experimental Validation Results for Cabozantinib S-malate
  • Experimental Validation Results for Cabozantinib S-malate
CAS No.: 1140909-48-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Cabozantinib S-malate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Cabozantinib S-malate

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB

All VEGFR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Cabozantinib S-malate Chemical Structure
    Cabozantinib S-malate Chemical Structure
    1/16
  • 1/16

    Cabozantinib S-malate purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [Abstract]

    Customer Validation
     Representative Western blots and densitometry show that cabozantinib reduces phosphorylation of Erk1/2 after 6 hours and reduces cyclin D1 and increases p27 protein levels after 24 hours of treatment (n=3-4).

  • 1/16

    Cabozantinib S-malate purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Sep 25;12(9):e0185321. [Abstract]

    Customer Validation
     Treatment with Cabozantinib results in complete inhibition of the c-MET phosphorylation stimulated by HGF at nanomolar concentrations.

  • 1/16

    Cabozantinib S-malate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Jan 14;59(1):358-73. [Abstract]

    Customer Validation
     Autophosphorylation of RET and its downstream signaling are blocked by 6i. The effect of 6i on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3 and (D) RET-V804M Ba/F3. (A-D) Ba/F3 cells, stably transformed with the indicated constructs, are treated for 1 h with gradually increasing concentrations of 7a, Cabozantinib and 6i (0-10 μM) and then lysed. Protein extracts are immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of R

  • 1/16

    Cabozantinib S-malate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Jan 14;59(1):358-73. [Abstract]

    Customer Validation
     Autophosphorylation of RET and its downstream signaling are blocked by 6i. The effect of 6i on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3 and (D) RET-V804M Ba/F3. (A-D) Ba/F3 cells, stably transformed with the indicated constructs, are treated for 1 h with gradually increasing concentrations of 7a, Cabozantinib and 6i (0-10 μM) and then lysed. Protein extracts are immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of R

  • Cabozantinib S-malate